Sign in
Taking people in United StatesPhase 2

Testing changed timing of spinal chemotherapy with blinatumomab for acute lymphoblastic leukemia

Tests methotrexate given into the spine with blinatumomab in adults with leukemia.

Key facts

Who runs it
Northside Hospital, Inc.
Where
Atlanta, United StatesSee the site
Trial code
Registry title
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Status
Recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
30 Jun 2023
Expected to end
1 Jun 2027
Type of study
Interventional
Treatments tested
  • Methotrexate
  • Blinatumomab
Record updated
14 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with B-cell acute lymphoblastic leukemia that came back, did not respond to treatment, or still shows leftover disease (MRD-positive). They are about to start their first cycle of blinatumomab.

Age
18 years or older
Sex
All sexes can join
Disease stage
B-cell acute lymphoblastic leukemia that is relapsed, refractory or MRD-positive
Earlier treatment
Must be receiving the first cycle of blinatumomab. People who had blinatumomab before cannot join.
Biomarker or test result
Negative for HIV. A negative serum pregnancy test, if applicable.

Main reasons for not taking part

  • Active leukemia in the brain or spinal fluid (CNS involvement)
  • Certain brain or nerve conditions, such as seizure, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's, cerebellar disease, psychosis, or coordination or movement disorder
  • Cannot receive intrathecal methotrexate
  • Prior treatment with blinatumomab
  • Another active cancer besides ALL

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Adults receiving first cycle of blinatumomab for relapse/refractory or MRD-positive B-cell Acute Lymphoblastic Leukemia
  • Adequate renal and hepatic function
  • Negative for HIV
  • Negative serum pregnancy test, if applicable
  • ECOG 0-2

Who cannot take part

  • Prior treatment with blinatumomab
  • Active infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator
  • Relative CNS disorders (seizure, paresis, aphasia, Cerebrovascular ischemia/hemorrhage, severe brain injury, dementia, Parkinson's, cerebellar disease, psychosis, coordination or movement disorder)
  • Active malignancy other than ALL
  • Active CNS involvement by ALL
  • Contraindication to receive intrathecal methotrexate

Where in United States

  • Northside HospitalAtlanta, United StatesContact: Caitlin Guzowski, MBA, MHATaking people

About the trial

What the trial wants to find out

Changing the schedule of intrathecal chemotherapy to be given before and during blinatumomab will maintain the anti-leukemic effects of this drug while at the same time adding the benefit of limiting the neurotoxicity associated with cytokine release.

The group in the trial

  • Intrathecal chemotherapy before blinatumomabTreatment being tested

    Treatment: Methotrexate and Blinatumomab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia
Plain-language title
Testing changed timing of spinal chemotherapy with blinatumomab for acute lymphoblastic leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
14 October 2026